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Abstract
Purpose This study aimed to retrospectively evaluate the genetic association of null variants of glutathione S-transferases 
GSTM1 and GSTT1 with relapse incidence in children with hematological malignancies (HMs) undergoing busulfan (BU)- 
containing allogeneic hematopoietic stem cell transplantation (HSCT) and to assess the impact of these variants on BU-
induced cytotoxicity on the immortalized lymphoblastoid cell lines (LCLs) and tumor THP1 GST gene-edited cell models.
Methods GSTM1- and GSTT1-null alleles were genotyped using germline DNA from whole blood prior to a conditioning 
BU-based regimen. Association of GSTM1- and GSTT1-null variants with relapse incidence was analyzed using multivariable 
competing risk analysis. BU-induced cell death studies were conducted in GSTs- null and non-null LCLs and CRISPR–Cas9 
gene-edited THP1 leukemia cell lines.
Results Carrying GSTM1/GSTT1 double null genotype was found to be an independent risk factor for post-HSCT relapse in 86 
children (adjusted HR: 6.52 [95% Cl, 2.76–15.42; p = 1.9 ×  10–5]). BU-induced cell death preferentially in  THP1GSTM1(non−null) 
and  LCLsGSTM1(non−null) as shown by decreased viability, increased necrosis and levels of the oxidized form of glutathione 
compared to null cells, while GSTT1 non-null cells showed increased baseline proliferation.
Conclusion The clinical association suggests that GSTM1/GSTT1 double null genotype could serve as genetic stratification 
biomarker for the high risk of post-HSCT relapse. Functional studies have indicated that GSTM1 status modulates BU-
induced cell death. On the other hand, GSTT1 is proposed to be involved in baseline cell proliferation.
Keywords Null genotypes of glutathione S-transferases · Acute leukemia · Hematological malignancies · Hematopoietic 
stem cell transplantation · Post-transplant relapse · Busulfan resistance
Background
Survival rates of children with hematological malignancies 
(HMs) undergoing allogeneic hematopoietic stem cell trans-
plantation (HSCT) have improved over the years achieving 
91% estimated 2-year overall survival. The improvement 
is mainly attributed to reduced HSCT-related toxicity and 
mortality. The incidence of post-HSCT relapse remains a 
significant complication and varies from 12 to 33% after 2 
years (Peters et al. 2021). Risk factors that influence trans-
plant success are on the one hand host- and disease related, 
such as disease genetics and remission status before HSCT, 
and on the other hand, transplant related, such as condition-
ing regimen and treatment-related toxicities including for 
example severe graft-versus-host disease (GvHD), sinusoi-
dal obstruction syndrome (SOS), and infections (Barrett and 
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Battiwalla 2010; Hamilton and Copelan 2012; Shah et al. 
2014).
A bifunctional alkylating agent busulfan (BU) is still 
often used in conditioning regimens prior to HSCT in 
children and adolescents (Philippe et al. 2016) and is com-
monly administered along with other chemotherapeutics, 
e.g., cyclophosphamide (CY) and fludarabine (FLU) (Ciu-
rea and Andersson 2009; Hao et al. 2020). At least in acute 
myeloid leukemia (AML), BU has shown lower long-term 
adverse effects, consequently replacing total body irradia-
tion (TBI) in the conditioning regimen (Lee et al. 2020). In 
acute lymphoblastic leukemia (ALL), although the recently 
published results showed lower rates of relapse after TBI-
containing conditioning, the results obtained with BU in 
association with FLU and thiotepa were encouraging and 
indicate an opportunity to find genetic subgroups of patients 
who might benefit from the TBI-free conditioning (Peters 
et al. 2021).
BU is metabolized via conjugation with glutathione 
(GSH) in the liver, which is predominantly catalyzed by 
glutathione S-transferase alpha1 (GSTA1) (Czerwinski 
et al. 1996). In hematopoietic cells (HCs), where GSTA1 
is not expressed (Czerwinski et al. 1997), other GST isoen-
zymes, particularly Mu1 (GSTM1, 46% of the BU conju-
gating activity of GSTA1 (Czerwinski et al. 1996)) might 
play the most important role. The role of GSTT1 in BU 
conjugation is not yet known, but has been mostly reported 
to have combined effects with GSTM1 on clinical outcomes 
(Kim et al. 2011; Myers et al. 2017). In addition to their 
protective role of the conjugation of BU in HCs, they might 
contribute to multiple cellular processes such as regulation 
of cell proliferation and apoptosis through the interaction 
with protein kinases such as apoptosis signal-regulating 
kinase 1 (ASK1). Under stress conditions, the interaction 
of the GSTM1:ASK1 complex is dissociated and results 
in activation of ASK1 that activates the c-Jun N-terminal 
kinase (JNK) and mitogen-activated protein kinase p38 
(MAPK p38) pathways, leading to upstream cytokine- and 
stress-induced apoptosis (Board and Menon 2013; Tew and 
Townsend 2012). However, the impact of apoptosis through 
kinases on BU-dependent cytotoxicity is poorly understood 
and even less whether those GST genes naturally knocked 
down might interfere in the post-HSCT relapse potential.
GSTM1 and GSTT1 genes can be homozygously deleted 
(presented as GSTM1-null and GSTT1-null) and thus com-
pletely deprived of the enzyme activities in a high percent-
age of individuals (the average % in Europe are 51 and 
19, respectively) (Saitou and Ishida 2015). In AML adult 
patients, Weiss et al. (Weiss et al. 2007) showed a perfect 
concordance of those variants in malignant and germline 
DNA, which suggests that the germline genotype drives 
protein expression in malignant cells. Although these vari-
ants have been associated with a higher risk of leukemia 
development (Li et al. 2018), there are conflicting reports on 
the association of the GSTM1-null and GSTT1-null variants 
with relapse in patients with HMs (Balta et al. 2003; Franca 
et al. 2012; Stanulla et al. 2000; Takanashi et al. 2003). To 
date, there is no evidence available for the association of 
germline GSTM1-null and GSTT1-null variants with post-
HSCT relapse in children with HMs.
Because GSTM1 and GSTT1 are the main remaining 
GSTs in HCs, we hypothesized that the absence of either 
or both proteins should affect BU cytotoxicity through 
conjugation-dependent or -independent ways, interfering 
in the HSCT outcomes. Hence, a genetic association study 
based on germline GSTT1- and GSTM1-null variants was 
undertaken. Further, we conducted in vitro functional analy-
ses to understand the role of these variants in survival and 
BU-induced apoptosis and necrosis of the immortalized and 




Pediatric patients with ALL, AML or myelodysplastic syn-
drome (MDS) who had undergone allogeneic HSCT between 
2000 and 2013 were enrolled in the study. The Institutional 
Review Board or ethics committees approved the study and 
all patients and/or parents provided informed consent. The 
present study is a subset of the multicentric study under 
the umbrella of the European Society for Blood and Mar-
row Transplantation (EBMT) (Clinicaltrials.gov identifier: 
NCT01257854) (Ansari et al. 2017).
I.v. BU (Busulfex, Otsuka Pharmaceuticals, Saint-Lau-
rent, Montreal, QC, Canada or Busilvex, Pierre Fabre Labo-
ratory, Paris, France) administration was given as a 2 h infu-
sion to the patients, every 6 h for a total of 16 doses. The 
first BU dose was age and weight based and pharmacoki-
netic (PK)-guided dose adjustment was performed to obtain 
a cumulative area under the curve (CumAUC) between 
59.2 and 98.56 mg*h/L as reported previously (Ansari et al. 
2017).
The primary diagnosis of HMs was made at the refer-
ring institution. Patients were considered to be in remis-
sion after chemotherapy if they presented < 5% blasts in 
the normal cellular bone marrow. Relapse in MDS was 
defined as > 5% and ≤ 20% of blasts at the bone marrow 
examination after engraftment and/or reappearance of 
major dysplastic features associated with cytopenias and/
or mixed chimerism > 5% and/or detection of the same 
cytogenetic abnormality present at diagnosis. Relapse in 
AML and ALL was defined as the presence of blasts in the 
Journal of Cancer Research and Clinical Oncology 
1 3
bone marrow > 5%, confirmed by flow cytometry; detec-
tion of the gene fusion present at diagnosis; or accord-
ing to minimal residual disease (MRD) results after the 
transplantation if available. Disease remission status 
was defined by the number of bone marrow remission or 
relapse events before HSCT.
Cumulative relapse incidence, event-free survival 
(EFS), and overall survival (OS) were defined according 
to the standard guidelines of EBMT and as detailed in our 
recent report (Ansari et al. 2017). EFS was calculated from 
the time of transplant until death, relapse, or graft failure, 
whichever occurred first. OS was calculated from the time 
of transplant until death from any cause.
Genotyping and statistical analysis
Genotyping of GSTM1-null and GSTT1-null variants was 
performed on germline DNA, extracted from whole blood 
or peripheral mononuclear cells of all patients before the 
first HSCT as described by Lin et al. (1998).
Pearson Chi-square test was used to analyze the differ-
ences in demographics between groups with and without 
GST-null variants. Estimated cumulative relapse incidence 
by competing risk analysis with non-relapse mortality as 
a competing event and the difference among groups were 
estimated by Gray’s test (Gray 1988). The Fine–Gray 
model was used for competing risk regression in multi-
variable analysis to obtain adjusted p values for all the 
variables in relation to the genotype groups (Fine and Gray 
1999). The potential risk factors with a p value ≤ 0.25 in 
the univariable competing risk analysis were retained in 
the multivariable analysis by including the GST geno-
type factor with the lowest p value. The final multivari-
able analysis included: diagnosis (ALL, AML and MDS), 
disease status [1st complete remission (CR), a higher 
degree of CRs and absence of CR], conditioning regimen 
(standard regimen with two alkylating agents and intensi-
fied regimen with three alkylating agents), AUC after the 
first dose of busulfan (1st BU dose AUC categorized into 
below 3.7, between 3.7 and 6.16, and above 6.16 mg*h/L) 
and BU CumAUC (below 59.2, between 59.2 and 98.6, 
and above 98.6 mg*h/L) as categorical variables. Cumula-
tive incidences of OS and EFS were estimated in relation 
to the genotype groups, using Kaplan–Meier framework 
and log-rank test. Univariate Cox regression was used to 
estimate hazard ratios.
All statistical analyses on clinical data were performed 
using SPSS (RRID: SCR_002865, Version 24.0. Armonk, 
NY: IBM Corp.) and R Project for Statistical Computing 
(version 3.6.2, RRID: SCR_001905) with Rcmdr package 
(version 2.6.1). Statistical power calculations according to 
GST variants were conducted in G*Power–Statistical Power 
Analyses for Windows and Mac, version 3.1.9.2 (RRID: 
SCR_013726; Dusseldorf, Germany).
In vitro functional studies of the associated variants
Cell models design and cell characterization
A set of 56 immortalized non-malignant lymphoblastoid 
cell lines (LCLs), acquired in 2012 from International 
HapMap Consortium’s CEPH Families Reference Panel 
142,011/147712 (Coriell Cell Repository, Camden, NJ, 
USA), and a human monocytic leukemia cell line (THP1; 
acquired in 2018 from ATCC, Cat# TIB-202, RRID: 
CVCL_0006; Manassas, Virginia, USA), derived from a 
1-year-old patient, were used for baseline and BU-induced 
functional assessment of GSTM1-null and GSTT1-null vari-
ants. The cells were immediately stored at − 196 °C and were 
not used prior to the start of experiments. The cell lines 
were thawed and cultured in Roswell Park Memorial Insti-
tute Medium (RPMI) 1640 medium (Gibco, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (HyClone, South 
Logan, UT) and 1% penicillin–streptomycin (Gibco) and 
incubated at 37 °C, 5%  CO2-humidified atmosphere accord-
ing to the manufacturer’s recommendations. The number of 
passages between thawing and use in each in vitro experi-
ment achieved the range between 5 and 15 times. The IDs of 
investigated LCLs used for each particular in vitro experi-
ment are listed in Supplementary Table 1.
THP1 GSTM1- and GSTT1-knockout cell lines 
 (THP1GSTM1(−/−) and  THP1GSTT1(−/−)) were prepared 
from parental THP1 representing non-null genotype for 
GSTM1  (THP1GSTM1(+/+)) and GSTT1  (THP1GSTT1(+/+)) 
using CRISPR/Cas9 gene-editing method. Plasmid PX458 
containing 5’-TGA TAC TGG GGT ACT GGG AC-3’ gRNA 
(GSTM1) or 5’-TGA AGG ACG GGG ACT TCA CC-3’ gRNA 
(GSTT1) (prepared by GeneScript, The Netherlands) was 
transfected into THP1 cells. 10,000 cells were fluorescence-
activated cell sorted (FACS) in 24-well plates based on the 
presence of green fluorescence protein (GFP) 48 h post-
transfection. After 48–72 h of recovery, THP1 cells were 
single-cell cloned in 96-well plates using FACS. Gene-mod-
ified clones were genotyped for the presence of deleterious 
mutations using Sanger sequencing and confirmed by West-
ern blot for the success of gene knockout. Five clones of the 
same genotype were pooled in a population.
DNA and proteins of the selected cell lines (LCLs, 
 THP1GSTM1(−/−) and  THP1GSTT1(−/−) cell models) were 
extracted using DNeasy Blood and Tissue Kit (Qiagen, 
Hilden, Germany) and standard protein extraction protocol 
for western blot using RIPA lysis buffer (Sigma-Aldrich, 
Germany), respectively. The intracellular concentration of 
extracted proteins was measured using Bradford assay from 
Bio-Rad (Hercules, CA) according to the manufacturer’s 
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recommendations. Aliquots containing 20 μg of proteins, 
sample reducing agent and LDS sample buffer (Thermo 
Fisher Scientific, USA) were subjected to electrophoresis 
by using Invitrogen Novex Tris–Glycine Gels (Thermo 
Fisher Scientific, USA). Dry transfer to a nitrocellulose 
membrane was performed with the iBlot dry blotting sys-
tem (ThermoFisher Scientific, USA). A membrane was 
blocked using 5% milk in PBS and 0.05% Tween 20. The 
following primary antibodies were used for protein labeling: 
ß-Actin Mouse monoclonal antibody (Abcam Cat# ab6276, 
RRID: AB_2223210); GSTP1 Monoclonal Antibody Rab-
bit (DSHB Cat# CPTC-GSTP1-1, RRID: AB_2617266); 
GSTM1 Monoclonal Antibody Mouse (Thermo FisherSci-
entific Cat# MA5-17,085, RRID: AB_2538556) and GSTT1 
Polyclonal antibody Rabbit (Thermo FisherScientific Cat# 
PA5-22,011, RRID: AB_11154445). Lumi-Light WB Sub-
strate (Roche, CH) was used for the detection of the sec-
ondary antibody linked with horseradish peroxidase (HRP). 
Band intensities were identified using Syngene G-Box Sys-
tem (Syngene, Frederick, MD, USA).
The glutathione transferase activity (Glutathione 
S-transferase [GST] Assay Kit, Sigma-Aldrich, USA) was 
measured on cell lysates obtained from one million cells 
 (THP1GSTM1(−/−) and  THP1GSTM1(+/+)) by measuring absorb-
ance at 340 nm every minute for 10 min in a 200 μl well of a 
96-well plate using Spectramax ID3 Multi-Mode microplate 
reader (Molecular Devices, USA) according to the manu-
facturer’s recommendations. GST activity was calculated as 
the following: [Δ340nm (min) * total volume of the reaction 
(ml)]/[5.3  mM−1 * volume of enzyme] corrected according 
to the protein concentration in mg/ml obtained by using a 
Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, 
USA) according to the manufacturer’s guidelines.
The results of the characterization of CRISPR–Cas9 
THP1 gene-edited cell models with target proteins (GSTM1, 
GSTT1 and GSTP1) and GST activity are presented in Sup-
plementary Fig. 1 (A–C).
DNA samples from LCLs were genotyped for GSTM1-
null and GSTT1-null variants using multiplex real-time PCR 
amplification in the presence of SYBR Green I and genotype 
discrimination by melting curve analysis in a StepOnePlus™ 
Real-Time PCR System (Applied Biosystems™, Foster City, 
CA, USA) with BCL2 (BCL2 apoptosis regulator) gene as 
an internal control as described earlier (Marin et al. 2010). 
The genotyping method used cannot differentiate the het-
erozygous individuals from homozygous non-null carriers 
(furtherly marked as GSTM1( +) and GSTT1( +)) except 
when using Sanger sequencing.
Cell viability, apoptosis, necrosis, GSSG/GSH measurements, 
and caspase activities
Intracellular ATP concentrations (CellTiter 2.0 Lumines-
cent Cell Viability Assay (Promega Corporation, Madi-
son, WI)) were screened in 56 LCLs and CRISPR–Cas9 
gene-edited cell models:  THP1GSTM1(−/−),  THP1GSTM1(+/+), 
 THP1GSTT1(−/−),  THP1GSTT1(+/+); at 48 h of treatment with 
100, 200, 400, 800 and 1600 µM concentrations of BU 
(Sigma-Aldrich, Germany) reconstituted with DMSO 
(Sigma), 1% of DMSO (as control) and at baseline (medium 
only). For validation of the first screening, ATP-independent 
cell viability follow-up (72 h) was performed at BU concen-
trations of 100, 250 and 500 µM in three GSTM1( +) and 
four GSTM1(-/-) LCLs (Supplementary Table 1) and at base-
line in  THP1GSTT1(−/−) and  THP1GSTT1(+/+) using RealTime-
GloMT Cell Viability Assay (Promega, USA).
Annexin V/PI assay (BD Biosciences) was used to meas-
ure live, early and late apoptotic and necrotic cells. Prior 
to FACS, ten GSTM1( +) and ten GSTM1(-/-) LCLs (Sup-
plementary Table 1) were treated for 48 h with BU (1% 
DMSO) at 250, 500 and 1000 µM and two samples of each 
cell line were used as controls (1% DMSO and untreated). 
One million cells were labeled according to the manufac-
turer’s protocol. FACS analysis was performed using the 
CyAN ADP system (Beckman Coulter, UK). Results were 
analyzed by Kaluza analysis software, version 1.3 (Beckman 
Coulter, UK). Apoptosis and necrosis were followed for 72 h 
in six GSTM1( +) and six GSTM1(-/-) LCLs (Supplemen-
tary Table 1) treated with 500 µM BU using RealTime-Glo 
MTAnnexin V Apoptosis and Necrosis Assay (Promega).
Concentrations of the total  (GSHT) (GSH-Glo Glu-
tathione Assays, Promega, USA) and oxidized intracellular 
glutathione (GSSG) (GSH/GSSG-Glo Glutathione Assays, 
Promega, USA) were measured according to the manufactur-
ers’ recommendations. Prior to measurement, cells from five 
GSTM1( +) and five GSTM1(−/−) LCLs and CRISPR–Cas9 
gene-edited THP1 cell models were incubated for 48 h at 
500 µM BU and 1% DMSO (control). Results are expressed 
as the relative proportion of GSSG to  GSHT.
Caspase-Glo 3/7 assay (Promega) was used to measure 
the total activity of caspases-3 and -7 in a subset of 12 LCLs 
(Supplementary Table 1) and CRISPR–Cas9 gene-edited 
THP1 cell models at 48 h BU post-treatment (250, 500 and 
1000 μM).
Chemiluminescent signals were measured using Victor3 
(Perkin Elmer, Inc., USA). All BU-based data were normal-
ized relative to the negative controls with 1% DMSO.
Statistical analyses in in vitro functional studies
The cell-based experiments  (IC50 distribution, end-point 
apoptosis and necrosis, real-time monitoring of viability, 
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apoptosis and necrosis, Caspase3/7 activities; and [GSSG/
GSHT] ratios) were performed at least in duplicate and 
results are reported as observed means ± SD stratified by 
GST-null and GST-non-null variants. Statistical differences 
between genotypes were assessed using Mann–Whitney, t 
tests, or two-way ANOVA according to the normality of 
the distribution and compared to untreated controls using 
GraphPad Prism 7 software (RRID: SCR_002798). We con-
sidered p < 0.05 to be statistically significant in all analyses.
Results
GSTM1‑ and GSTT1‑double null genotypes are 
associated with higher relapse incidence
Eighty-s ix  ch i ldren  wi th  mal ignancies  aged 
5 months–18 years (female/male, 44/42), who received mye-
loablative conditioning containing four-times-daily i.v. BU 
followed by HSCT, were enrolled in this study. The patients’ 
baseline characteristics at the time of their HSCT are sum-
marized in Table 1. The number of patients who had expe-
rienced relapse was 16 (18.6% of included patients) with 
the median time to onset 203 days (range 35 to 817) and 12 
(14.0%) patients died with the median time to onset 221 days 
(range 15 to 979). The median CumAUC of BU achieved 
56.96 mg*h/L (concentration range 30.50–115.23 mg*h/L).
Regarding the genotype frequency, 49 patients were 
GSTM1-null (57.0%), 24 GSTT1-null (27.9%) and 9 had null 
genotypes in both GSTM1 and GSTT1 genes (10.5%). Char-
acteristics of these patients according to GSTM1-null and 
GSTT1-null variants are shown in Supplementary Table 2.
Relapse was associated with GSTT1-null compared to 
GSTT1-non-null subgroups (42.1% vs 16.1%) in the univari-
able analysis (p = 0.04, Fig. 1A, Table 2A). The GSTM1-null 
was not associated with relapse (Fig. 1B, Table 2A). How-
ever, patients carrying null genotypes in both GSTM1 and 
GSTT1 genes showed significantly increased risk of relapse 
compared to other genotype subgroups ([GSTM1-non-null/
GSTT1-non-null, GSTM1-non-null/GSTT1-null and GSTM1-
null/GSTT1-non-null]; p = 0.012, Fig. 1C, Table 2A) and 
this risk remained significant when other genotype sub-
groups were grouped together (using a gene–gene interaction 
model; 77.8% vs. 19.0%; p = 0.002, Fig. 1D, Table 2B). Sig-
nificantly lower EFS was observed in the group of patients 
carrying (−/−) alleles in both GSTM1 and GSTT1 genes 
in comparison to others (54.2% vs. 11.1%, p < 0.001, Sup-
plementary Fig. 2A). When gene variants were analyzed 
independently, none of them affected the EFS (data not 
presented). OS was not significantly associated with GST-
null variants (using gene–gene interaction model; 67,1% vs. 
37,0%, p = 0.401, Supplementary Fig. 2B).
Table 1  Demographic and transplantation characteristics of pediatric 
patients at the time of HSCT and events follow-up
ALL acute lymphoblastic leukemia; AML acute myeloid leukemia; 
BM, bone marrow; BU, busulfan; CB cord blood; CR1 first complete 
remission; CR2 second complete remission; CR3 third complete 
remission; HLA identical sibling; MDS myelodysplastic syndrome; 
MMUD non-identical unrelated; MMRD non-identical related; MUD 
identical unrelated; MRD  identical related; ND no data; PBSCs 
peripheral blood stem cells
*Disease phase “CR3 or more” included all patients either in CR3 or 
more or in partial remission or those with > 10% of circulating myelo-
blasts before conditioning
# 2 alkylating agents (busulfan with cyclophosphamide or melphalan) 
and 3 agents (busulfan/cyclophosphamide with melphalan or etoposide)
































 CR3 or more* 9 (10,5)
 Never treated 24 (27,5)
 ND 5 (5,8)
Intensity of  conditioning#
 2 66 (76,7)
 3 or more 20 (23,3)
Median (range)
Age at HSCT (years) 6,5 (0,5–18,2)
Weight (kg) 24,5 (6,0–87,9)
Height (cm) 122,5 (51,0–183,0)
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Relapse was compared between GSTM1-null and 
GSTT1-null variants combined with other possible risk 
factors (Table  2B). GSTM1/GSTT1 double null status 
was independently associated with relapse with an HR of 
6.52 [95% Cl, 2.76 – 15.42; p = 1.9 ×  10–5]. 25%, 9.7% and 
23.3% of patients with ALL, MDS and AML, respectively, 
were relapsed. Among them, all relapsed patients with the 
GSTT1-null genotype had ALL (Supplementary Table 3).
Canada), The Hospital for Sick Children (Toronto, Ontario, Canada), 
Robert Debre University Hospital (Paris, France), Leiden University 
Medical Center (Leiden, Netherlands) and Geneva University Hospi-
tal (Geneva, Switzerland)
Table 1  (continued)
Fig. 1  Cumulative incidence plots of relapse in univariable com-
peting risk analyses stratified by GST-null variants. Results are 
plotted for (A) GSTT1(−/−) group versus groups GSTT1( ±) and 
GSTT1(+ / +) together presented as GSTT1( +); (B) GSTM1(−/−) 
group versus groups GSTM1( ±) and GSTM1(+ / +) together pre-
sented as GSTM1( +); (C) combined GSTM1(−/−)/GSTT1(−/−) 
versus other genotype combinations [GSTM1(−/−)/GSTT1( +), 
GSTM1( +)/GSTT1(−/−) and GSTM1( +)/GSTT1( +)]; (D) combined 
GSTM1(−/−)/GSTT1(−/−) versus grouped other genotype  combina-
tions [GSTM1( +)/GSTT1( +)]. p values for the difference in cumula-
tive incidence of relapse were calculated with Gray’s test with death 
as a competing event. HR, hazard ratio; GSTM1-null and GSTT1-null 
are presented as GSTM1(−/−) and GSTT1(−/−), respectively. GSTM1 
non-null and GSTT1 non-null genotypes are presented as GSTM1( +) 
and GSTT1( +), respectively
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Table 2  Relationship between GSTM1-null and GSTT1-null variants and other risk factors with a cumulative incidence of relapse in univariable 
and multivariable competing risk analyses (Fine–Gray’s test)
adj adjusted; ALL acute lymphoblastic leukemia; AML acute myeloid leukemia; AUC_day1 area under the curve for BU after the first dose 
of BU; 95% CI 95% confidence interval; CRisk, competing risk analysis of the cumulative incidence of relapse with competing event death; 
CRRisk multivariate competing risk regression analysis that is presented with Fine–Gray proportional hazard ratios (HR); CR1, first complete 
remission; CR2, second complete remission; CR3, third complete remission; HR, hazard ratio; disease status; CumAUC , cumulative area under 
the curve for BU; MDS myelodysplastic syndrome
A)
Covariable Univariable analysis
HR 95% Cl p value (C Risk)
GSTM1 genotype
0.372
 GSTM1( +) (N=37) Reference 1
 GSTM1(−/−) (N=49) 1.627 (0.586–4.514)
GSTT1 genotype
0.040
 GSTT1( +)(N=62) Reference 1
 GSTT1(−/−)(N=24) 2.822 (1.058–7.528)
GSTM1 and GSTT1 genotypes (4 groups)
0.012
 GSTM1( +) and GSTT1( +)(N=22) Reference 1
 GSTM1(−/−) and GSTT1(−/−)(N=9) 12.836 (2.218–74.274)
 GSTM1(−/−) and GSTT1( +)(N=40) 1.879 (0.378–9.354)
 GSTM1( +) and GSTT1(−/−)(N=15) 2.614 (0.478–14.300)
B)
Covariable Univariable analysis Multivariable analysis
HR 95% Cl p value (CRisk) HR 95% Cl p value (CRRisk)
GSTM1 and GSTT1 genotypes (2 groups)
 GSTM1( +)/GSTT1( +) and GSTM1(−/−)/
GSTT1( +) and GSTM1( +) /
GSTT1(−/−)(N=77)
Reference 1 0.002 Reference 1 1.9 × 10–5
 GSTM1(−/−) and GSTT1(−/−)(N=9) 7.190 (2.165–23.874) 6.521 (2.758–15.420)
Diagnosis
 ALL Reference 1 0.232 Reference 1 0.093
 AML 1.077 (0.296–3.925)
 MDS 0.384 (0.077–1.902) 0.503 (0.225–1.121)
Cum_AUC (mg*h/L)#
  < 59.2 Reference 1 0.062 Reference 1 0.220
 59.2–98.6 3.891 (1.327–11.409) 3.947 (0.432–36.040)
  > 98.6 1.741 (0.201–15.055)
AUC_1stDose (mg*h/L)
  < 3.7 Reference 1 0.090 Reference 1 0.410
 3.7–6.16 0.729 (0.089–5.983) 0.391 (0.041–3.737)
  > 6.16 2.230 (0.276–17.991)
Intensity of conditioning
 2 Reference 1 0.134 Reference 1 0.100
 3 or more 0.382 (0.086–1.687) 0.338 (0.091–1.248)
Disease phase
 CR1 Reference 1 0.166 Reference 1 0.800
 CR2 1.088 (0.230–5.140) 1.058 (0.688–1.626)
 CR3 or more 2.042 (0.651–6.786)
 Never treated 0.329 (0.070–1.555)
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LCL sensitivity to BU is associated with GSTM1, 
but not with GSTT1 genotypes
Significantly higher cell viability after treatment with BU 
was observed in LCLs with GSTM1-null genotype (1.8-fold, 
p = 0.013) and  THP1GSTM1(−/−) cells (1.5-fold, p = 0.0006) 
compared to GSTM1-non-null by 48 h end point (Fig. 2A, 
B, respectively) and the results were confirmed by 72-h 
kinetic measurements in LCLs (Supplementary Fig. 3). 
GSTT1-null, alone or in combination with GSTM1-null, did 
“CR3 or more” included all patients either in CR3 or more or in partial remission or those with > 10% of circulating myeloblasts before condi-
tioning
*Intensity of conditioning, two alkylating agents (busulfan with cyclophosphamide or melphalan) and three agents (busulfan/cyclophosphamide 
with melphalan or etoposide)
# CumAUC was calculated after 16 doses administered in 6 h intervals and is presented in mg*h/L of which one dose 3.7 mg*h/L is equivalent to 
900 μM × min and 6.16 mg*h/L is equivalent to 1500 μM × min
Bold: significant p values below 0.05
GSTM1-null and GSTT1-null are presented as GSTM1(−/−) and GSTT1(−/−), respectively. GSTM1 non-null and GSTT1 non-null genotypes are 
presented as GSTM1( +) and GSTT1( +), respectively
Table 2  (continued)
Fig. 2  IC50-values for BU in GSTM1-null and GSTT1-null LCLs, 
 THP1GSTM1(−/−) and  THP1GSTT1(−/−) cells. IC50 values for BU were 
stratified according to GSTM1- (A) and GSTT1-null variants (C) 
in LCLs and CRISPR–Cas9 gene-edited  THP1GSTM1(−/−) (B) and 
 THP1GSTT1(−/−) (D) cell models. Concentration–response titration 
points were fitted to a Hill equation for BU. The 50% inhibitory 
concentrations of BU (BU-IC50) were determined by dose–response 
curve fitting using Prism 5.02 software (GraphPad SoftwareInc., CA. 
USA). The coefficient of determination (R2) of each plate was used 
to assess experimental reproducibility and was set to be above 0.95. 
Independent experiments were repeated at least three times. Non-
parametric unpaired t test was used in LCLs (A, C). Pairwise com-
parisons by t test between GST(−/−) variants in THP1-CRISPR–Cas9 
models (B., D.) were used. In THP1-CRISPR–Cas9 cell models (B., 
D.), dots represented are specific clones with identified GST(−/−) 
variants (+ / + vs. −/−) based on Sanger DNA-sequencing. p values 
below 0.05 were considered statistically significant. ns, not signifi-
cant. GSTM1-null and GSTT1-null are presented as GSTM1(−/−) and 
GSTT1(−/−), respectively. GSTM1 non-null and GSTT1 non-null 
genotypes are presented as GSTM1( +) and GSTT1( +), respectively
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not show a significant association with BU-IC50 in LCLs 
and  THP1GSTT1(−/−) cell lines (Fig. 2C, D, respectively). No 
difference in baseline cell proliferation was seen between 
GSTM1-null and GSTM1- non-null cells (Fig. 3A), while the 
proliferation of GSTT1-null cells was significantly decreased 
in comparison to GSTT1-non-null carriers in LCLs carry-
ing GSTT1-null genotype and  THP1GSTT1(−/−) [p = 0.03 
(LCL, 48 h end-point measurement, Fig. 3B) and p < 0.05 
 (THP1GSTT1(−/−), 72 h kinetic plot, Fig. 3C)].
GSTM1‑null genotype is associated with increased 
apoptosis and decreased primary necrosis after BU 
treatment
In a subgroup of ten GSTM1-null LCLs, we observed 
increased early apoptosis and a decreased primary necrosis 
(p = 0.026 and 0.006, respectively) at 48 h post-treatment 
with 250, 500 and 1000 µM of BU in comparison to ten 
GSTM1-non-null LCLs (Fig. 4A–D). No significant differ-
ences between both GSTM1 genotype groups were observed 
for the number of live cells and apoptotic cells at a later stage 
(the mix of necrotic and real apoptotic cells). Apoptosis was 
further assessed through measurement of caspase 3/7 activ-
ity according to GST(−/−) variants showing significantly 
higher activation in GSTM1-null LCLs and  THP1GSTM1(−/−) 
at 250, 500 and 1000 µM BU in comparison to GSTM1-
non-null cells (p < 0.05; Fig. 4E), while no differences were 
observed at baseline. BU-induced activation of caspase 3/7 
was not significant in GSTT1-null LCLs (p = 0.21), while 
in  THP1GSTT1(−/−) was significantly decreased (p = 0.002; 
Fig. 4E) in comparison to GSTT1-non-null cells.
Cell death mechanisms were further followed by kinetic 
plots. We observed higher apoptotic rates in GSTM1-null 
cells  (THP1GSTM1(−/−), LCLs) through the whole 72 h of 
follow-up after BU treatment when compared to GSTM1-
non-null cells from unrelated individuals (Supplementary 
Figs. 4A and 4C, p < 0.0001 and p = 2.6E-05, respectively). 
In contrast, we observed lower necrotic rates in GSTM1-
null cells  (THP1GSTM1(−/−), LCLs) that were increasing after 
26 h of BU treatment when compared to GSTM1-non-null 
cells (Supplementary Figs. 4B, D, p < 0.001 and 1.4E-05, 
respectively). Apoptosis at the same time points was lower 
Fig. 3  Baseline cell growth against GSTM1-null and GSTT1-null gen-
otypes in LCLs and  THP1GSTT1(−/−) cells. Baseline cell growth was 
assessed against GSTM1-null (A) and GSTT1-null (B) genotypes in 
LCLs at 48 h end-point analysis and the (C) RealTime Cell Viabil-
ity assay–Kinetics plot was performed for 72 h stratified by GSTT1-
null genotype at baseline (proliferation profile) in  THP1GSTT1(−/−) 
cell models. (A, B) On the y-axis, the basal cell growth rate (r) was 
calculated using the following formula, appropriate for the usual 
exponential kinetics of cell growth (N; the number of cells) after the 
defined time (t; h):  Nt =  No.2tr. (C) Measurement of baseline reduc-
ing the potential of viable cells according to GSTT1(−/−) variant in 
CRISPR–Cas9 gene-edited cell models was performed. The unpaired 
t test between GST genotypes in LCLs (A., B.) and Pairwise com-
parisons by t test between GSTT1 genotypes in THP1-CRISPR–
Cas9 models were used. p values below 0.05 were considered sta-
tistically significant. GSTM1-null and GSTT1-null are presented 
as GSTM1(−/−) and GSTT1(−/−), respectively. GSTM1 non-null 
and GSTT1 non-null genotypes are presented as GSTM1( +) and 
GSTT1( +), respectively
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in these cells accounting for the faster cell death, mainly as 
a result of primary necrosis.
[GSSG/GSHT] ratios are higher in GSTM1‑non‑null 
LCLs and  THP1GSTM1(+/+) cells after BU treatment 
compared to GSTM1‑null while total GSH levels 
remain unchanged
At baseline, no differences in [GSSG/GSHT] ratios were 
observed between null and non-null LCLs and THP1 cells 
for the GSTM1 gene. However, 48 h after 500 μM BU treat-
ment, [GSSG/GSHT] ratios were increased 1.6- (p = 0.02, 
LCLs) and 1.3-fold (p = 0.005, THP1) in GSTM1 non-null 
compared to GSTM1-null (Fig. 5A, C, respectively). A simi-
lar trend was observed after the 250 μM BU treatment (48 h) 
in  THP1GSTM1(−/−) in comparison to  THP1GSTM1(+/+) cells 
(Fig. 5C). In THP1, no significant difference was observed 
according to GSTT1 genotype after the treatment with BU or 
at baseline (Fig. 5D). In addition, we observed a significant 
increase in total GSH levels after the 500 μM BU treatment, 
irrespective of the GSTM1 genotype (Fig. 5B, p=0.001), 
thus indicating the potential for BU-related induction of 
GSH synthesis.
Discussion
Our clinical association study performed in 86 children with 
HMs undergoing HSCT following BU-based conditioning 
regimens demonstrated that patients harboring homozygous 
deletions in both GSTM1 and GSTT1 genes presented a high 
risk of relapse  (HRrelapse 7.2 [95% Cl, 2.2–23.9; p = 0.002]) 
and a lower EFS  (HREFS 4.092 [95% Cl, 1.829–9.152; 
p = 0.001]). After adjustment for known risk factors (diag-
nosis, disease status, the intensity of conditioning regimen 
and BU exposure), the association remained significant 
demonstrating that the deletion of both GST genes is an 
independent risk factor for relapse (adjusted HR 6.52 [95% 
CI, 2.8–15.4; p = 1.9 ×  10–5]). Although it is a small cohort, 
this is the first report on the risk of post-HSCT relapse in 
relation to the germline GSTM1- and GSTT1-null variants 
in children with HMs. Until now, only one study conducted 
in BU/CY-based HSCT settings although in adults showed 
increased relapse rates in patients carrying GSTM1-null 
genotype, while no association was identified with GSTT1-
null genotype (Terakura et al. 2020). Concerning non-trans-
plant-based studies in pediatric or adult patients, a similar 
association between GSTM1/GSTT1 double null carriers and 
increased risk of relapse (Barragan et al. 2007; Borst et al. 
2012; Takanashi et al. 2003, Xiao Q. et al. 2014), lower 
complete remission rate (Xiao Z. et al. 2008) and lower 
EFS were demonstrated (Chen et al. 1997; Hall et al. 1994; 
Leonardi et al. 2017; Rocha et al. 2005; Stanulla et al. 2000; 
Takanashi et al. 2003; Teachey and Hunger 2013; Woo et al. 
2000; Zhang et al. 2017). There are nevertheless a few stud-
ies showing no such association (Franca et al. 2012; Zareifar 
et al. 2013), in which the small number of patients or the 
different treatment regimens may have mainly precluded 
defining a relationship between GST variants.
Based on the known detoxifying role of GSTs, our results 
from the clinical association are contradictory. Although 
GSTA1 is the main enzyme involved in BU detoxification, 
GSTM1 is also highly expressed in the liver and recognized 
as involved in BU conjugation (Ansari et al. 2017; Bremer 
et al. 2015; Czerwinski et al. 1996; Kim et al. 2011), pre-
cluding the BU to cross-link with the DNA strands. Func-
tional variants of the genes coding for GSTs may then inter-
fere in HSCT by affecting BU metabolism. It is known that 
low BU exposure (CumAUC < 59 mg × h/L) is associated 
with graft failure and relapse (Ansari et al. 2017; Bartelink 
et al. 2016; Philippe et al. 2016), whereas high BU expo-
sure (CumAUC > 98.6 mg × h/L) could reduce post-HSCT 
relapse in leukemia at the cost of an increase in organ 
toxicities, and therefore transplantation-related mortality 
(Ansari et al. 2017; Bartelink et al. 2016; McCune et al. 
2002; McCune and Holmberg 2009; Philippe et al. 2016). 
However, at the level of HCs, less is known about the direct 
effect of BU.
We compared BU-related cell death mechanisms in LCLs 
and THP1 with and without GSTM1 and/or GSTT1 genes 
after exposure to BU. LCLs were chosen as the in vitro 
model to resemble heterogeneity seen in a clinical cohort. 
Since each LCL is derived from a different individual genetic 
background, the studied effect due to BU is specifically 
related to the GSTM1- and GSTT1-null and –non-null geno-
types. The acute monocytic leukemia (THP1) cell model was 
selected for the production of the CRISPR–Cas9 GSTM1- 
and/or GSTT1 knockout model, as we have the most patients 
with a relapsed AML (Supplementary Table 3). Selection of 
these two cell models aids in evaluating BU-dependent and 
-independent GSTT1 and GSTM1 effects. We demonstrated 
Fig. 4  Number of necrotic and apoptotic cells in LCLs and caspase 
3/7 activity in LCLs,  THP1GSTM1(−/−) and  THP1GSTT1(−/−) cells. Flow 
cytometric analysis (FACS) by using Annexin V/PI assay was used 
to assess primary necrosis (A), late apoptosis (B), live cells (C) and 
early apoptosis (D) in LCLs stratified according to GSTM1-null vari-
ants; and caspase 3/7 activity (E) in LCLs and THP-CRISPR–Cas9 
models stratified according to GST-null variants at 250, 500 and 
1000 μM BU 48 h post-treatment. Statistical analysis was performed 
by two-way ANOVA considering 250, 500 and 1000 μM BU concen-
trations (genotype and treatment factors); t tests between GST(−/−) 
variants in each condition separately were used; no statistically signif-
icant differences were observed between GSTM1 + and GSTM1(−/−) 
LCLs and THP-CRISPR–Cas9 models in either 1% DMSO or 
medium only; p values below 0.05 were considered statistically sig-
nificant. GSTM1-null and GSTT1-null are presented as GSTM1(−/−) 
and GSTT1(−/−), respectively. GSTM1 non-null and GSTT1 non-null 
genotypes are presented as GSTM1( +) and GSTT1( +), respectively
◂
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that only GSTM1-null (but not GSTT1-null) is associated 
with higher resistance to BU as determined by higher 
BU-IC50 values of GSTM1-null LCLs and  THP1(GSTM1−/−) 
in comparison to GSTM1-non-null cells. This could be due 
to a change in the redox equilibrium as demonstrated by 
lower levels of oxidized GSH, lower primary necrosis and 
higher early apoptosis. An increase of GSTM1-null LCL’s 
viability was confirmed either by continuous follow-up 
of redox potential within 72 h. Apoptosis/necrosis kinetic 
results demonstrate that BU-induced apoptotic processes 
are more pronounced in GSTM1-null LCLs. In contrast, pri-
mary necrotic cell death was more pronounced in GSTM1-
non-null cells when comparing with the GSTM1-null cells. 
In addition, primary necrosis was significantly induced at 
an earlier stage in GSTM1-non-null cells. These results 
show that GSTM1-null variants can modulate BU-induced 
cell death, which were supplemented further by increased 
activation of known apoptotic markers caspase-3 or -7 in 
GSTM1-null LCLs and THP1 in comparison to GSTM1-non-
null cells. Importantly, observed reduced rates of GSTM1-
dependent cell death cannot be attributed to the increased 
baseline cell proliferation.
The findings of higher primary necrosis, lower early 
apoptosis and lower cell viability in GSTM1-non-null HCs 
compared to GSTM1-null cells treated with BU were unex-
pected. Contrary to our observations, many studies showed 
associations between increased expression or activity of 
GSTs and resistance mechanisms against a range of cyto-
toxic drugs (Hoban et al. 1992; Smith et al. 1989). These 
results could potentially be explained by not only direct 
detoxification with GSH, but also through negative regu-
lation of pro-apoptotic protein kinases, such as apoptosis 
signal-regulating kinase 1 (ASK1) (Board and Menon 2013; 
Tew and Townsend 2012). For instance, stress conditions 
cause the release of ASK1 from GSTM1, thereby leading to 
induction of apoptosis, which was shown in our experiments 
Fig. 5  Glutathione levels in LCLs stratified according to GSTM1-
null variant,  THP1GSTM1(−/−) and  THP1GSTT1(−/−) cells. [GSSG/GSHT] 
ratio (A) and  GSHT (B) in LCLs were calculated stratified according 
to GSTM1-null variant; and [GSSG/GSHT] ratios in CRISPR–Cas9 
edited  THP1GSTM1(−/−) (C) and  THP1GSTT1(−/−) (D) cell models after 
the treatment with 500 μM BU. Statistical analysis was performed by 
the two-way ANOVA considering 250 or 500 μM BU concentration 
(genotype factor); t tests between GST(−/−) variants in each condi-
tion separately were used; no statistically significant differences were 
observed between GST(−/−) variants in LCLs and THP-CRISPR–
Cas9 models in either 1% DMSO or medium; p values below 0.05 
were considered statistically significant. GSTM1-null and GSTT1-null 
are presented as GSTM1(−/−) and GSTT1(−/−), respectively. GSTM1 
non-null and GSTT1 non-null genotypes are presented as GSTM1( +) 
and GSTT1( +), respectively
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after induction with BU. In addition, GSTM1-null cells car-
rying more free ASK1 for phosphorylation activation are 
expected to have more apoptosis upon BU-induced stress 
in comparison to GSTM1-null cells which is in accordance 
with our in vitro results.
However, the observed paradox in increased cell death 
of GSTM1 well-expressed cells upon BU treatment could 
additionally be explained by findings of the study of DeLeve 
et al. (2000), demonstrating that in murine hepatocytes BU 
is cytotoxic also through oxidative stress caused by BU 
metabolites (BU glutathione S-conjugate thiophenium ion, 
 GS+THT) and by the depletion of GSH in addition to DNA 
alkylation. The toxic metabolites of BU/GSH metabolism 
are mainly oxidized by flavin-containing monooxyge-
nases (FMOs, e.g., FMO3) and cytochromes (CYPs, e.g., 
CYP3A4) (El-Serafi et al. 2017) to water-soluble non-toxic 
metabolites [e.g., sulfolane (Uppugunduri et al. 2017)]. 
However, CYP3A4 and FMO3 are mainly expressed in the 
liver (accounting for 54% of overall tetrahydrothiophene 
[THT] disappearance, the metabolite of BU), and less in 
LCLs, as observed in our laboratory (data not shown) and by 
others (https:// www. prote inatl as. org). After RNA sequenc-
ing in LCLs, very low or no gene expressions of CYP 2D6, 
2C19, 2C9, 2B6, 2C8, 4A11, 3A4, FMO1 and FMO3 were 
identified. In this context, the oxidative burst caused by elec-
trophilic molecules from BU–GSH conjugation (Udensi and 
Tchounwou 2014; Zmorzynski et al. 2015) in addition to the 
absence of CYP3A4 and FMO3 could be a reason for the 
lower sensitivity of GSTM1-null HCs to BU, as observed 
in LCLs and THP1. In contrast, higher total expressions of 
CYPs and FMOs in hepatocytes (El-Serafi et al. 2017) could 
explain why GSTA1-slow BU metabolizing individuals in 
addition to the absence of GSTM1 activity show potentially 
more treatment-related toxicities [e.g., SOS (Srivastava et al. 
2004) and aGvHD (Elhasid et al. 2010)] than carriers with 
normal GST’s enzyme activities. A hypothetical compara-
tive model of the difference in BU fate between hepatocytes 
and lymphocytes is suggested in Supplementary Fig. 5 and 
warrants further investigation.
The genetically determined different cell fate after BU 
exposure might explain the apparently discordant results 
between the relapse incidence in patients carrying GSTM1-
null genotype (in combination with GSTT1-null) and 
the cellular resistance to BU in GSTM1-null LCLs and 
 THP1GSTM1(−/−). The higher rates of necrosis in GSTM1-
non-null cells might predict a pro-inflammatory cell death 
of the malignant cells, resulting in enhanced immunogenic-
ity (Sachet et al. 2017). Unlike the other chemotherapeutic 
regimens including autologous transplantation, the efficacy 
of the allogeneic transplantation relies on the graft-versus-
leukemia effect, especially in HMs (Horowitz et al. 1990; 
Yeshurun et al. 2019), but that theory should be further 
explored.
Another relevant observation is the significantly increased 
post-HSCT relapse in GSTT1-null when combined with 
GSTM1-null genotype in children with HMs. The link 
between GSTT1 and post-HSCT relapse is not clear yet. Our 
in vitro observations cannot be attributed to the BU-related 
differences in  IC50 values or [GSSG/GSHT] ratios. Other 
pharmacogenomics studies also demonstrated that genetic 
variations in GSTT1 are not associated with BU clearance 
or liver toxicity (Gaziev et al. 2010; Goekkurt et al. 2007; 
Kim et al. 2011; Srivastava et al. 2004). Nevertheless, we 
observed faster baseline proliferation in GSTT1-non-null 
LCLs/THP1 and a slightly higher baseline increase of cas-
pase 3/7 activation compared to those with GSTT1-null 
genotype, indicating GSTT1 potential involvement of BU- 
independent mechanisms in the relapse development.
The results of the present clinical study are limited by 
the retrospective study design and relatively small pediatric 
sample size with no clinical validation cohort. However, the 
sample size of 86 patients has at least 80% power with 10% 
of observed combined GSTM1/GSTT1 double null variants’ 
frequency and relapse incidence with the estimated observed 
effect size of ≥ 7.0 and alpha value of 0.05. The primary 
diagnosis of HMs was made at the referring institution and 
was not centrally reviewed. Well-known risk factors such 
as somatic genetic/cytogenetics abnormalities, the donor 
DNA and the initial response to the treatment (e.g., MRD) 
were not available. However, as described in Supplementary 
Table 2, similar characteristics were present between the 
GST genetic subgroups (p values > 0.05). The GST-null vari-
ants were not associated with the status of the disease before 
HSCT and we assume that the germline genotype impact on 
protein expression was present in malignant cells as shown 
by Weiss et al. (2007). The majority of cases in our study 
underwent a BU–CY conditioning regimen; however, it is 
not known if this association is specific to a BU–CY condi-
tioning regimen only or unspecific to other chemotherapeu-
tics used in the HSCT setting (e.g., Thio or Mel) (Hao et al. 
2020). For instance, active metabolites of CY (e.g., acrolein) 
are also eliminated by GSH conjugation catalyzed by GSTs 
(Uppugunduri et al. 2017). This needs to be evaluated in 
the future with a focus on whether GSTs play a major role 
in determining clinical outcomes. This aspect is currently 
being evaluated by our group using a cohort from multiple 
centers with the usage of multiple conditioning regimens. 
Furthermore, the transplant-related mortality or combined 
toxicities were not associated with the GSTM1- and GSTT1-
null variants (data are not shown), suggesting compensation 
of BU conjugation by other GSTs, especially GSTA1, which 
is mainly expressed in hepatocytes and other somatic cells.
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Conclusions
In summary, we report that GSTM1/GSTT1 double null 
genotypes could serve as genetic biomarkers for identifying 
pediatric patients with HMs at higher risk of relapse after an 
allogeneic HSCT following BU-containing conditioning. On 
the other hand, the absence of those markers might predict 
the patients who more likely will respond to the chemother-
apy-based conditioning. Functional studies indicated differ-
ent mechanisms of cell death upon exposure to BU based on 
the presence or absence of GST-null alleles and the in vivo 
impact of those findings must be further explored.
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